Irving Investors focuses on disruptive technology and high growth opportunities.
Irving was founded in 2009 as a dedicated equity fund focused on disruptive technology and high growth opportunities, and has since expanded into Credit and Private investments. Irving was founded in 2009 as a dedicated equity fund focused on disruptive technology and high growth opportunities and has since expanded into credit and private investments. The fund looks to form meaningful relationships with companies by offering its capital, expertise, and connections to promote growth and return on investment.Irving has been involved in several successful private exits and is a trusted advisor and LP in Venture Capital funds.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 12, 2022
Snyk
|
Series G | $196.50M | Cyber Security | — |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
Aug 2, 2021
InterVenn
|
Series C | $201M | Biotechnology | — |
Mar 23, 2021
Absci
|
Series Unknown | $125M | Artificial Intelligence | — |
Nov 9, 2020
Prometheus Biosciences
|
Private Equity(PE) | $130M | Biotechnology | — |